Insight Molecular Diagnostics Inc.
IMDX Healthcare Diagnostics & Research
Insight Molecular Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, up 115.6% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3.33% and free cash flow fell 54.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow IMDX
Insight Molecular Diagnostics Inc. (IMDX) EV/Sales
As of 16 October 2026, Insight Molecular Diagnostics Inc. (IMDX) trades at a EV/Sales of 55.7×. Over the past ten years it has ranged from −204× (August 2022) to 345× (February 2021); the current reading is higher than 85% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 53.7× | 61.62% |
| FY2024 | 33.3× | 175.08% |
| FY2023 | 12.1× | (44.14%) |
| FY2022 | 21.6× | (70.75%) |
| FY2021 | 74.0× | (40.08%) |
| FY2020 | 124× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 119× | 170.46% |
| Mar 2026 | 44.1× | (17.92%) |
| Dec 2025 | 53.7× | 165.83% |
| Sep 2025 | 20.2× | 15.54% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBAI MBody AI Ltd. compare | n/m |
| MDXH MDxHealth SA compare | 0.8× |
| PRPO Precipio, Inc. compare | 1.3× |
| BDSX Biodesix, Inc. compare | 2.5× |
| XGN Exagen Inc. compare | 2.6× |
| QUCY Quantum Cyber N.V compare | 8.4× |
| BNR Burning Rock Biotech Limited Sponsored ADR compare | 17.9× |
| MDXHF MedX Health Corp. compare | 29.4× |
| IMDX Insight Molecular Diagnostics Inc. | 55.7× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)